301 related articles for article (PubMed ID: 22963717)
1. The interaction between ER and NFκB in resistance to endocrine therapy.
Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
[TBL] [Abstract][Full Text] [Related]
2. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
3. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
Frasor J; El-Shennawy L; Stender JD; Kastrati I
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
[TBL] [Abstract][Full Text] [Related]
4. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
5. The NF-KB pathway and endocrine therapy resistance in breast cancer.
Khongthong P; Roseweir AK; Edwards J
Endocr Relat Cancer; 2019 May; 26(6):R369-R380. PubMed ID: 32013374
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
[TBL] [Abstract][Full Text] [Related]
7. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
Smart E; Semina SE; Frasor J
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
[TBL] [Abstract][Full Text] [Related]
8. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
Frasor J; Weaver A; Pradhan M; Dai Y; Miller LD; Lin CY; Stanculescu A
Cancer Res; 2009 Dec; 69(23):8918-25. PubMed ID: 19920189
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
10. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.
Pradhan M; Bembinster LA; Baumgarten SC; Frasor J
J Biol Chem; 2010 Oct; 285(41):31100-6. PubMed ID: 20705611
[TBL] [Abstract][Full Text] [Related]
12. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
[TBL] [Abstract][Full Text] [Related]
13. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Mancuso MR; Massarweh SA
Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
[TBL] [Abstract][Full Text] [Related]
15. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
16. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
Pathiraja TN; Stearns V; Oesterreich S
J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):35-47. PubMed ID: 20101445
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.
De Marchi T; Foekens JA; Umar A; Martens JW
Drug Discov Today; 2016 Jul; 21(7):1181-8. PubMed ID: 27233379
[TBL] [Abstract][Full Text] [Related]
19. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
20. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.
Kurebayashi J
Breast Cancer; 2003; 10(2):112-9. PubMed ID: 12736563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]